Muratovska A, Lightowlers R N, Taylor R W, Turnbull D M, Smith R A, Wilce J A, Martin S W, Murphy M P
Department of Biochemistry, University of Otago, PO Box 56, Dunedin, New Zealand.
Nucleic Acids Res. 2001 May 1;29(9):1852-63. doi: 10.1093/nar/29.9.1852.
The selective manipulation of mitochondrial DNA (mtDNA) replication and expression within mammalian cells has proven difficult. One promising approach is to use peptide nucleic acid (PNA) oligomers, nucleic acid analogues that bind selectively to complementary DNA or RNA sequences inhibiting replication and translation. However, the potential of PNAs is restricted by the difficulties of delivering them to mitochondria within cells. To overcome this problem we conjugated a PNA 11mer to a lipophilic phosphonium cation. Such cations are taken up by mitochondria through the lipid bilayer driven by the membrane potential across the inner membrane. As anticipated, phosphonium-PNA (ph-PNA) conjugates of 3.4-4 kDa were imported into both isolated mitochondria and mitochondria within human cells in culture. This was confirmed by using an ion-selective electrode to measure uptake of the ph-PNA conjugates; by cell fractionation in conjunction with immunoblotting; by confocal microscopy; by immunogold-electron microscopy; and by crosslinking ph-PNA conjugates to mitochondrial matrix proteins. In all cases dissipating the mitochondrial membrane potential with an uncoupler prevented ph-PNA uptake. The ph-PNA conjugate selectively inhibited the in vitro replication of DNA containing the A8344G point mutation that causes the human mtDNA disease 'myoclonic epilepsy and ragged red fibres' (MERRF) but not the wild-type sequence that differs at a single nucleotide position. Therefore these modified PNA oligomers retain their selective binding to DNA and the lipophilic cation delivers them to mitochondria within cells. When MERRF cells were incubated with the ph-PNA conjugate the ratio of MERRF to wild-type mtDNA was unaffected, even though the ph-PNA content of the mitochondria was sufficient to inhibit MERRF mtDNA replication in a cell-free system. This unexpected finding suggests that nucleic acid derivatives cannot bind their complementary sequences during mtDNA replication. In summary, we have developed a new strategy for targeting PNA oligomers to mitochondria and used it to determine the effects of PNA on mutated mtDNA replication in cells. This work presents new approaches for the manipulation of mtDNA replication and expression, and will assist in the development of therapies for mtDNA diseases.
事实证明,在哺乳动物细胞内选择性操纵线粒体DNA(mtDNA)的复制和表达颇具难度。一种很有前景的方法是使用肽核酸(PNA)寡聚物,即能选择性结合互补DNA或RNA序列从而抑制复制和翻译的核酸类似物。然而,PNA的潜力因难以将其递送至细胞内的线粒体而受到限制。为克服这一问题,我们将一个11聚体PNA与一个亲脂性鏻阳离子偶联。此类阳离子可通过线粒体内膜跨膜电位驱动穿过脂质双层而被线粒体摄取。正如预期的那样,分子量为3.4 - 4 kDa的鏻 - PNA(ph - PNA)偶联物被导入分离的线粒体以及培养的人类细胞内的线粒体中。这通过使用离子选择性电极测量ph - PNA偶联物的摄取得以证实;通过细胞分级分离结合免疫印迹法;通过共聚焦显微镜;通过免疫金电子显微镜;以及通过将ph - PNA偶联物与线粒体基质蛋白交联得以证实。在所有情况下,用解偶联剂耗散线粒体膜电位可阻止ph - PNA的摄取。ph - PNA偶联物选择性抑制含有导致人类mtDNA疾病“肌阵挛性癫痫伴破碎红纤维”(MERRF)的A8344G点突变的DNA的体外复制,但不抑制在单个核苷酸位置不同的野生型序列的复制。因此,这些修饰的PNA寡聚物保留了它们与DNA的选择性结合,并且亲脂性阳离子将它们递送至细胞内的线粒体中。当将MERRF细胞与ph - PNA偶联物一起孵育时,MERRF与野生型mtDNA的比例未受影响,尽管线粒体中的ph - PNA含量足以在无细胞系统中抑制MERRF mtDNA的复制。这一意外发现表明,核酸衍生物在mtDNA复制过程中无法结合其互补序列。总之,我们开发了一种将PNA寡聚物靶向线粒体的新策略,并利用它来确定PNA对细胞中突变mtDNA复制的影响。这项工作为操纵mtDNA复制和表达提供了新方法,并将有助于开发针对mtDNA疾病的疗法。